title: [Research advances of anti-CD40 monoclonal antibody].
abstract: CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive biological effects. After stimulating CD40 signal, it can exert corresponding function through MAPK (JNK, ERK, p38) pathway, PI3K cascade, as well as NF-κB and STAT. The CD40 signal is closely related to tumor immunity, this moleculer has already become targeted-molecule for cancer treatment. Recently, there have been many anti-CD40 monoclonal antibodies displaying good anti-cancer effect, among which CHIR-12.12, SGN-40 and CP-870, 893 developed rapidly and successively have entered clinical research stage. This review focuses the status of anti-CD40 monoclonal antibody, including distribution of CD40, physiological function of CD40, CD40 and tumor immunity, anti-CD40 monoclonal antibodies and so on.
authors.affiliation: Academy of Military Medical Sciences, Beijing, China.
authors.forename: Long-Long
authors.initials: LL
authors.lastname: Luo
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Chun-Mei
authors.initials: CM
authors.lastname: Hou
authors.forename: Chun-Xia
authors.initials: CX
authors.lastname: Qiao
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D019013:CD40 Antigens / Q000276:immunology*; D006801:Humans; D009369:Neoplasms
chemical_list: D000911:Antibodies, Monoclonal; D019013:CD40 Antigens